1614

Sheet 1 of 3 APPLICATION NO ATTY DOCKET NO. 10/743,952 10173-111-999 LIST OF REFERENCES CITED BY APPLICANT APPLICANT . (Use several sheets if necessary) Dasseux et al. GROUP FILING DATE

U.S. PATENT DOCUMENTS

December 24, 2003

			NAME	CL	ASS	SUBCLASS		FILING CLASS IF APPRO	
				1	1	1			
A01	6,143,755	<u> </u>		-		 			
A02	6,124,309	l		-	├ —		-		
A03	6,093,719	7/25/00	Bocan	<u> </u>	<u> </u>				
A04	6,093,744	7/25/00	Lee et al.	<u> </u>	_	<u> </u>	 _		<u> </u>
A05	6,017,905	1/25/00	Roark et al.	<u> </u>	↓_	ļ	1		
	5,981,595	11/9/99	Picard et al.		_	ļ	\bot		
L	5,968,963	10/19/99	Homan		1_	<u> </u>	1		L
	5,783,600	6/21/98	Bisgaier et al.					ļ <u>-</u>	
	5,756,344	5/26/98	Onda et al.			<u> </u>	\perp		
├	5,756,544	5/26/98	Bisgaier et al.						
├─	5,750,569	5/12/98	Bisgaier et al.						
<u> </u>	5,648,387	7/15/97	Bisgaier et al.				\perp	<u> </u>	
L	5,633,287	5/27/97	Lee et al.						
	5,578,639	11/26/96	Homan			<u> </u>	\perp		
ļ	5,504,073	4/2/96	Homan			<u> </u>		<u> </u>	
 	5,502,198	3/26/96	Picard et al.				\perp	<u> </u>	
—	4,711,896	12/8/87	Bar-Tana et al.		\mathbf{I}_{-}		\perp		<u> </u>
+	4,689,344	8/25/87	Bar-Tana						<u> </u>
+	1 (0 (0 10	1/6/87	Takaishi et al.				\perp		
	4 612 502	9/23/86	Yamatsu et al.				\perp		
		4/22/86	Manghisi et al.			<u> </u>	\perp		
	1 005 000	9/1/81	Kawamatsu et al.				\perp		
		12/30/75	Creger						
-	1 016	11/20/73	Creger	$\cdot $			\perp		
		4/29/69	Blake et al.		\Box				1
	A02 A03 A04 A05 A06 A07 A08 A09 A10 A11 A12 A13 A14 A15 A16 A17 A18 A19 A20 A21 A22 A23 A24	A02 6,124,309 A03 6,093,719 A04 6,093,744 A05 6,017,905 A06 5,981,595 A07 5,968,963 A08 5,783,600 A09 5,756,344 A10 5,756,544 A11 5,750,569 A12 5,648,387 A14 5,578,639 A15 5,504,073 A16 5,502,198 A17 4,711,896 A18 4,689,344 A19 4,634,719 A20 4,613,593 A21 4,584,321 A22 4,287,200 A23 3,930,024 A24 3,773,946	A01 6,143,755 11/7/00 A02 6,124,309 9/26/00 A03 6,093,719 7/25/00 A04 6,093,744 7/25/00 A05 6,017,905 1/25/00 A06 5,981,595 11/9/99 A07 5,968,963 10/19/99 A08 5,783,600 6/21/98 A09 5,756,344 5/26/98 A10 5,756,544 5/26/98 A11 5,750,569 5/12/98 A12 5,648,387 7/15/97 A13 5,633,287 5/27/97 A14 5,578,639 11/26/96 A15 5,504,073 4/2/96 A16 5,502,198 3/26/96 A17 4,711,896 12/8/87 A18 4,689,344 8/25/87 A19 4,634,719 1/6/87 A20 4,613,593 9/23/86 A21 4,584,321 4/22/86 A22 4,287,200 9/1/81 A23 3,930,024 12/30/75 A24 3,773,946	A01 6,143,755 A02 6,124,309 A03 6,093,719 A04 6,093,744 A05 6,017,905 A06 5,981,595 A07 5,968,963 A08 5,783,600 A09 5,756,344 A10 5,756,544 A11 5,750,569 A12 5,648,387 A13 5,633,287 A14 5,578,639 A15 5,504,073 A16 5,502,198 A17 4,711,896 A18 4,689,344 A19 4,634,719 A19 4,634,719 A10 4,584,321 A20 4,613,593 A21 1/20/73 A21 A12 A23 3,930,024 A24 3,773,946 A24 3,773,946 A24 1/20/60 A08 Bocan Boca	A01 6,143,755	A01 6,143,755 117//00 Bocan A02 6,124,309 9/26/00 Bocan A03 6,093,719 7/25/00 Lee et al. A04 6,093,744 7/25/00 Roark et al. A05 6,017,905 11/25/00 Roark et al. A06 5,981,595 11/9/99 Picard et al. A07 5,968,963 10/19/99 Homan A08 5,783,600 6/21/98 Bisgaier et al. A09 5,756,344 5/26/98 Onda et al. A10 5,756,544 5/26/98 Bisgaier et al. A11 5,750,569 5/12/98 Bisgaier et al. A12 5,648,387 7/15/97 Bisgaier et al. A13 5,633,287 5/27/97 Lee et al. A14 5,578,639 11/26/96 Homan A15 5,504,073 4/2/96 Homan A16 5,502,198 3/26/96 Picard et al. A17 4,711,896 12/8/87 Bar-Tana et al. A18 4,689,344 8/25/87 Bar-Tana A19 4,634,719 11/6/87 Takaishi et al. A20 4,613,593 9/23/86 Yamatsu et al. A21 4,584,321 4/22/86 Manghisi et al. A22 4,287,200 9/1/81 Kawamatsu et al. A23 3,930,024 12/30/75 Creger A20 3,773,946 11/20/73 Creger	A01 6,143,755 11/7/00 Bocan A02 6,124,309 9/26/00 Bocan A03 6,093,719 7/25/00 Bocan A04 6,093,744 7/25/00 Lee et al. A05 6,017,905 11/25/00 Roark et al. A06 5,981,595 11/9/99 Picard et al. A07 5,968,963 10/19/99 Homan A08 5,783,600 6/21/98 Bisgaier et al. A10 5,756,544 5/26/98 Onda et al. A11 5,750,569 5/12/98 Bisgaier et al. A12 5,648,387 7/15/97 Bisgaier et al. A13 5,633,287 5/27/97 Lee et al. A14 5,578,639 11/26/96 Homan A15 5,504,073 4/2/96 Homan A16 5,502,198 3/26/96 Picard et al. A17 4,711,896 12/8/87 Bar-Tana et al. A18 4,689,344 8/25/87 Bar-Tana A19 4,634,719 1/6/87 Takaishi et al. A20 4,613,593 9/23/86 Yamatsu et al. A21 4,584,321 4/22/86 Manghisi et al. A22 4,287,200 9/1/81 Kawamatsu et al. A23 3,930,024 12/2007 Blake et al. A19 According the following the following terms of the control of the c	DOCUMENT NUMBER 11/7/00 Bocan	DOCUMENT NUMBER DATE NAME CLASS SUBCLASS IF APPE

<i>-</i>			· ·	N PATENT DOCUMENTS	CLASS	SUBCLASS	TRANSL	
		DOCUMENT NUMBER	DATE	COUNTRY	T CLASS	SODELLIS	YES	NO
<u> </u>	B01	WO 01/46110	6/28/01	PCT				
	B02	WO 00/64911	11/2/00	PCT			<u></u>	
CA	B03	WO 99/00116	1/7/99	PCT .				<u> </u>
IA	B04	WO 98/30530	7/16/98	PCT			<u> </u>	<u> </u>
CA	B05	WO 96/30328	10/3/96	PCT		<u> </u>	<u> </u>	<u>L</u> ,

		OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
CA	C01	Acton et al., 1996, "Identification of scavenger receptor SR-BI as a high density lipoprotein receptor," Science 271:518-520
	C02	Badimon et al., 1992, "Role of high density lipoproteins in the regression of atherosclerosis, Circulation and Supplication of the control of
CA	C03	III):86-94 Barrans et al., 1996, "Pre-beta HDL: structure and metabolism," Biochem. Biophys Acta 1300:73-85
CA	C04	Bisgaier et al., 1998, "A novel compound that elevates high density lipoprotein and activates the peroxisome
CA	C05	Brown and Goldstein, 1990, "Drugs used in the treatment of hyperhipoprotein and Silvery and Pergamon Press Ch. 36, pp. 874-896
CA	C06	Bruce et al., 1998, "Plasma lipid transfer proteins, high density inpoproteins, and reverse endesters transfer,
CA	C07	Dansky and Fisher, 1999, "High-density lipoprotein and plaque regression: the good cholesterol gets even better,
	C08	Decossin et al., 1997, "Subclasses of LpA-1 in coronary artery disease: distribution and choicstero error and all choicstero errors and all choicstero errors are all and choicstero errors."
CA (A	C09	Fielding and Fielding, 1995, "Molecular physiology of reverse cholesterol transport," J. Lipid Res. 50.211-220
CA	C10	Gearing et al., 1993, "Interaction of the peroxisome proliferator activated receptor and retinoid X receptor," Proc. Natl Acad. Sci. USA 90:1440-1444
CA	C11	Harris and Kletzien, 1994, "Localization of a programme response element in the authoryte ratty acta of the state of the s
(A	C12	Heyman et al., 1992, "9-cis retinoic acid is a high affinity ligand for the retinoid X receptor, Centrol 297-400
CA	C13	Hidaka and Fidge, 1992, "Affinity purification of the hepatic high density lipoprotein receptor identifies two acidic glycoproteins and enables further characterization of their binding properties," Biochem. J. 284:161-167
CA	C14	Hirano et al., 1997, "Genetic cholesteryl ester transfer protein deficiency is extremely in equal in the orning at the orning and associated with longevity," Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity," 1,7,1052,1059
CA	C15	Issemann and Green, 1990, "Activation of a member of the steroid hormone receptor supertaintly by peroxisome
CA	C16	Keller and Wahli, 1993, "Peroxisome proliferator-activated receptors - a link between endocrinology and nutrition,
CA	C17	Keller et al., 1993, "Fatty acids and retinoids control lipid metabolism through activation of peroxisome profiterator
CA	C18	Kliewer et al., 1992, "Convergence of 9-cis retinoic acid and peroxisome proliterator signature pattways unough
CA	C19	Kurata et al., 1998, "A candidate high density lipoprotein (HDL) receptor, HB", with possible multiple full cultures. Language "I Atheroscler and Thromb. 4:112-117
CA	C20	Lagrost et al., 1996, "Opposite effects of cholesteryl ester transfer protein and phospholipid transfer protein on the size distribution of plasma high density lipoproteins. Physiological relevance in alcoholic patients," J. Biol. Chem.
IA	C21	271:19058-19065 Landschulz et al., 1996, "Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in live and steroidogenic tissues of the rat," J. Clin. Invest. 98:984-995
IA	C22	Lazarow and Fujiki, 1985, "Biogenesis of peroxisomes," Annu. Rev. Cell Biol. 1:469-330
(A	C23	Levin et al., 1992, "9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRa," Nature 355:359-361
(A	C24	Nan F et al. "Dual Function Glutamate-Related Ligands: Discovery of A Novel, Potent Inhibitor of Glutamate On the provided U. Respecting mGluR3. Agonist Activity." Journal of Medicinal Chemistry 2000, 43:pgs.772-774
· CA	C25	Nemali et al., 1988, "Comparison of constitutive and inducible levels of expression of peroxisonial p-oxidation and
CA	C26	Parra et al., 1992, "A case control study of lipoprotein particles in two populations at contrasting risk to coronary
CA	C27	Reaven, 1993, "Role of insulin resistance in human disease (syndrome X): an expanded definition, Aintal News Medical 1993,
CA	C28	Reddy and Lalwani, 1983, "Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of
CA	C29	Rigotti et al., 1996, "Regulation by adrenocorticotropic hormone of the <i>in vivo</i> expression of scavenger receptor class B type I (SR BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland," J. Biol.
CA	C30	Robins and Fasulo, 1997, "High density lipoproteins, but not other lipoproteins, provide a venicle for sterot transport
TA	C31	1008 "Regulation of ano A-I gene expression by tibrates." Atheroscierosis 13/(Suppl.):519-523

Express Mail No. <u>EV 452 772 876 US</u>

Sheet 3 of 3

CA	C32	hormone receptors, PPARy and RXRa," N	•	odimeric	complex of	two nuclear	
CA	C33	Vamecq and Draye, 1989, "Pathophysiolo	gy of peroxisomal β-oxidation," Essa	ays Biocl	hem. <u>24</u> :115	-225	
EXAMINER		AULAKY	DATE CONSIDERED	10	127	105	
		reference considered, whether or not citation is in co y of this form with next communication to applicant		ough citat	ion if not in co	onformance and	not

Sheet 1 of 1 ATTY DOCKET NO. APPLICATION NO 10173-111-999 (CAM #371855-999106) 10/743,952 ERENCES CITED BY APPLICANT APPLICANT (Use several sheets if necessary) Dasseux et al. GROUP FILING DATE December 24, 2003 1614 **U.S. PATENT DOCUMENTS** *EXAMINER FILING DATE INITIAL DOCUMENT NUMBER DATE NAME CLASS **SUBCLASS** IF APPROPRIATE FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUBCLASS TRANSLATION YES NO WO 02/30860 A2 10/11/01 PCT/US01/31872 **B05** OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not

EXAMINER

considered. Include copy of this form with next communication to applicant.

NYJD: 1550832.1